NKTR News 10.97 Nektar Therapeutics (NKTR)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 18, 2014 at 12:46 AM

Nektar Therapeutics (NKTR) 10.97 $NKTR

Nektar Presents Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:10PM CDT
Nektar presented preclinical data on NKTR-102 and NKTR-214 at the AACR.

Watch List for Equities Hitting New High -- Research on Nektar Therapeutics, Clean Diesel Technologies, MeetMe, and Bazaarvoice
PR Newswire - Thu Apr 10, 12:06PM CDT
The US markets finished on a positive note on Wednesday, April 09, 2014, with the NASDAQ Composite closing at 4,183.90, up 1.72%, the Dow Jones Industrial Average ending the session at 16,437.18, up 1.11%, and the S&P 500 gained 1.09% to finish the trading session at 1,872.18. The gains were broad based as eight out of ten sectors finished on a positive note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Nektar Therapeutics (NASDAQ: NKTR), Clean Diesel Technologies Inc. (NASDAQ: CDTI), MeetMe Inc. (NYSE: MEET) and Bazaarvoice Inc. (NASDAQ: BV). Free technical research on NKTR, CDTI, MEET and BV can be downloaded upon signing up at:

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
at The Street - Thu Apr 10, 10:52AM CDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.

Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR
PR Newswire - Wed Apr 09, 8:00AM CDT
Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technologies, today announced that preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 Annual Meeting of the American Association of Cancer Research (AACR) being held in San Diego, California.

Nektar Rises on FDA Notification (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 1:50PM CDT
If approved, naloxegol would be the first once-daily oral treatment for patients with chronic OIC.

Uptrend Call Working As Nektar Therapeutics Stock Rises 21.0% (NKTR)
Comtex SmarTrend(R) - Thu Mar 20, 9:21AM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 4 months, Nektar Therapeutics has returned 20.96% as of today's recent price of $14.31.

Nektar Rises on FDA Notification - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 5:16PM CDT
Nektar's shares gained more than 9% on Mar 18.

Nektar Therapeutics Has Returned 12.9% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Wed Mar 12, 5:19PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 4 months, Nektar Therapeutics has returned 12.93% as of today's recent price of $13.36.

Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar
PR Newswire - Thu Mar 06, 7:25AM CST
Editor Note: For more information about this release, please scroll to bottom.

Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.

Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 10:10AM CST
Nektar reported a loss of 41 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 16 cents.

Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 27, 8:27AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...

Downgrade Alert for Nektar Therapeutics (NKTR)
Comtex SmarTrend(R) - Thu Feb 27, 7:02AM CST
Nektar Therapeutics (NASDAQ:NKTR) was downgraded from Buy to Neutral at MKM Partners today. The stock closed yesterday at $13.70 on volume of 919,000 shares, below average daily volume of 1.2 million. Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
PR Newswire - Wed Feb 26, 3:15PM CST
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2013.

Nektar Therapeutics Up 13.5% Since SmarTrend Uptrend Call (NKTR)
Comtex SmarTrend(R) - Wed Feb 26, 10:06AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 13.48% as of today's recent price of $13.43.

3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Dan Carroll, The Motley Fool - Motley Fool - Sun Feb 23, 3:53PM CST
No industry embraces the boom-or-bust potential of the stock market like the biotech industry. Under-the-radar stocks can produce huge returns for investors from successful drug approvals, milestone achievements, and other events. But which stocks...

Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets
PR Newswire - Wed Feb 19, 3:15PM CST
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday, February 26, 2014, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

Uptrend Call Working As Nektar Therapeutics Stock Rises 16.2% (NKTR)
Comtex SmarTrend(R) - Wed Feb 19, 9:22AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on November 22nd, 2013 at $11.83. In approximately 3 months, Nektar Therapeutics has returned 16.23% as of today's recent price of $13.75.

European Data Centre Services Market
PR Newswire - Thu Feb 13, 4:53AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Michael Lee-Chin: Wealth Strategies and Life Lessons

Embracing Opportunity and Adversity When you think of someone who’s made a real dent in the business world, Michael Lee-Chin’s journey might just stop you in your tracks. Here’s a guy who went from standing on the 'dunce' side of the class in Jamaica to transforming himself into one of the few Black billionaires on this planet. That transformation is no small feat,...

Revolutionizing Textiles: Touchscreen Garments Emerge

Picture a world where your shirt does more than just cover your back. Bingo, folks—smart textiles have taken center stage with groundbreaking technology that melds touchscreens with fabric, and the brains behind it hail from the National University of Singapore (NUS). It's not just about slapping a few LEDs onto a vest. We're talking about clothing that can display...

CTG Data Breach Sparks Class Action Investigation

CTG Faces Scrutiny Over Recent Data Breach Ah, the thrills and spills of the digital age—yet another company stumbling headfirst into a data breach mess. This time, it’s Computer Task Group (CTG) taking center stage, with its IT systems compromised and personal info slipping through the cracks. On September 26, 2026, an unwelcome guest rooted around their network,...

Roofr Unveils AI Tools: Shaping Roofing's Future

Making Waves in Roofing: Roofr's Big Moves Listen up, folks. When a company like Roofr announces new tech, contractors better pay attention. The roofing industry—often overlooked by the flashy tech scene—just got hit with some slick new tools. Today, Roofr held its semi-annual virtual event, Roofr Builds, unraveling a slew of updates that might just streamline the way...

Local Visibility Crisis Looms for Small Businesses

Scrolling through these fresh stats from BrightLocal's recent report, you can almost hear the alarm bells echoing across small towns and city squares. The data paints a surprisingly sobering picture: despite the fact that 71% of folks are heading straight to Google to find local businesses, only a mere 22% of small business owners are tagging it as one of their top tools...

Tune In for Post Holdings' Earnings Call this November

Crunch Time for Post Holdings: Earnings Insight Well folks, pull out your calendars because November 20 is shaping up to be a big day for those tracking Post Holdings, Inc. (NYSE:POST). If you're in the game, this upcoming conference call is your prime chance to get the scoop on how the numbers stack up for Q4 and what's brewing for fiscal year 2027. This isn't some...

Corgi Invest Shakes Up Bond ETFs with Low Fees

A Different Breed of Bond ETFs Well, folks, when you thought the ETF scene couldn't get any more crowded, Corgi Invest pops in with a pack of 14 new bond ETFs, barking up the low-expense tree like there's no tomorrow. They've dropped these puppies into the market with fees starting as low as 0.02%, aiming to take a bite out of their pricier rivals. The Alpha of Low-Cost...

Sony's Game-Changing Sensor Reshapes Medical Endoscopy

In a world where medical tech innovation can make the difference between life and death, Sony’s latest feat will turn some heads in the healthcare industry. This ain’t about another PlayStation release; we’re talking the IMX742 CMOS image sensor crafted for single-use endoscopes. As far as breakthroughs go, the microscopic square sensor packs a surprising punch by...

QFIN Investors Eye Class Action Amid Regulatory Struggles

QFIN Shareholders Unite Amid Regulatory Storm It's not every day you see a stock nosedive by nearly 19% overnight. But when you're investing in a company like Qfin Holdings, you get ready for a wild ride, especially when regulatory changes from China come into play. That's exactly what's happening right now as investors rally around a class action lawsuit against Qfin....

California Contractors Honored for Safety Commitment

Commitment to Safety in the Construction Industry When it comes to construction, safety isn’t an afterthought—it’s woven into the very fabric of every project. The 39th Annual Construction Safety Excellence Awards by the Associated General Contractors of California (AGC of California) pits a spotlight on those embodying this ethos. Industry Leaders in Safety Held on...